Compare EFC & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | DMRA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | 500 | 7 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | EFC | DMRA |
|---|---|---|
| Price | $13.59 | $20.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $14.55 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 996.0K | 308.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.05 | N/A |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.28 | $16.50 |
| 52 Week High | $14.12 | $28.76 |
| Indicator | EFC | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 33.97 |
| Support Level | $13.23 | N/A |
| Resistance Level | $13.74 | $27.70 |
| Average True Range (ATR) | 0.18 | 1.97 |
| MACD | -0.02 | -0.30 |
| Stochastic Oscillator | 62.22 | 21.42 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.